Holen Sie sich die Stockscreener-App
97.93
1.00%
0.97
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$96.96
Offen:
$96.8
24-Stunden-Volumen:
1.92M
Relative Volume:
0.88
Marktkapitalisierung:
$15.50B
Einnahmen:
$4.34B
Nettoeinkommen (Verlust:
$-965.00M
KGV:
-16.13
EPS:
-6.07
Netto-Cashflow:
$869.00M
1W Leistung:
-2.12%
1M Leistung:
+9.46%
6M Leistung:
-28.35%
1J Leistung:
-18.32%
1-Tages-Spanne:
$96.17
$98.41
1-Wochen-Bereich:
$95.75
$100.40
52-Wochen-Spanne:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
97.93 | 15.84B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
424.98 | 162.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.79 | 147.08B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
518.71 | 43.52B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.36 | 35.27B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
163.25 | 28.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche - Yahoo
What drives Illumina Inc. stock priceExplosive capital gains - Jammu Links News
Illumina Inc. Stock Analysis and ForecastMarket-beating returns - Jammu Links News
Illumina’s SWOT analysis: genomics giant faces headwinds as stock outlook shifts - Investing.com
Single-Cell Omics Market Growth in Future Scope 2025-2032 |10x - openPR.com
DNA Microarray Market Size, Industry Growth Insights Report - openPR.com
Bioinformatics Market Set to Witness Significant Growth by 2033 - openPR.com
How To Trade (ILMN) - news.stocktradersdaily.com
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Illumina stock downgraded at Scotiabank (ILMN:NASDAQ) - Seeking Alpha
Scotiabank Downgrades Illumina to Sector Perform From Sector Outperform, Reduces Price Target to $125 From $164 - MarketScreener
Genomics in Germany - Illumina
Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 - 富途牛牛
Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year - PR Newswire
Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit - simplywall.st
Illumina Shares Fall After Citigroup Downgrade - MarketScreener
Why Illumina (ILMN) Shares Are Falling Today - Yahoo Finance
Illumina: Citigroup downgrades to 'Sell' Rating, The Target Price is $80 - AInvest
Illumina stock down as Citi cuts on recent rally (ILMN:NASDAQ) - Seeking Alpha
Illumina Shares Slip After Citi Issues Bearish Rating Ahead of Earnings - MSN
Where Illumina Stands With Analysts - Nasdaq
Illumina Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Illumina to Acquire SomaLogic for $350 Million, Expanding into Proteomics and Precision Medicine - Insider Monkey
The Jackson Laboratory advances precision medicine with an end-to-end NGS workflow - Illumina
Illumina, Inc. (ILMN): A Bull Case Theory - Insider Monkey
Canaccord Raises Price Target Of Illumina, Inc. (ILMN). - Insider Monkey
Infinity Bio Secures $8M Series A and Acquires Serimmune to Dominate Antibody Reactome Market - Stock Titan
DNA/Gene Microarray Market Future Trends and Scope Analysis - openPR.com
How the DNA Data Storage Market Will Evolve by 2032Growth, - openPR.com
Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire Inc.
Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com
Illumina and Science Centre Singapore partner for Brain Fest 2025 - Illumina
Video: Inspiring the next generation of scientists in Singapore - Illumina
Clinical Oncology Next Generation Sequencing Market Detailed - openPR.com
Illumina (ILMN) Price Target Boosted by Canaccord Analyst | ILMN Stock News - GuruFocus
Video: Two Illumina scientists share their “why” - Illumina
Breaking Down Illumina: 11 Analysts Share Their Views - Benzinga
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - Illumina
Lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - marketscreener.com
Piper Sandler maintains Illumina stock Overweight, $185 target By Investing.com - Investing.com UK
Long Read Sequencing Market Top Key Players Analysis - openPR.com
Gemeinsam Genomik neu denken - Illumina
Microarray Biochips Market is Booming Worldwide |Illumina,Qiagen,Eppendorf - openPR.com
Single-cell Omics Market Projected to Witness Growth with - openPR.com
Tumor-Derived Exosomes Market Set to Witness Significant - openPR.com
Hereditary Testing Market Future Business Opportunities - openPR.com
Next Generation Sequencing Market to Witness Upsurge in Growth - openPR.com
Does Illumina (ILMN) Have Good Long-Term Growth Prospects? - Insider Monkey
Nucleic Acid Isolation and Purification Market Size, Trends & - openPR.com
Illumina’s DNA Test Tech Infringes Hospital Patent, Suit Claims - Bloomberg Law News
Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.54%
3.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):